QUEBEC CITY, April 15 /CNW Telbec/ - AEterna Zentaris Inc. (TSX: AEZ;
Nasdaq: AEZS), a global biopharmaceutical company focused on endocrine therapy
and oncology, today announced that it will present two posters on its PI3K
inhibitor compound, AEZS-126, as well as a poster on its orally-active tubulin
and topoisomerase II inhibitor compound, AEZS-112, at the American Association
for Cancer Research (AACR) Annual Meeting, to be held on April 18-22, 2009 at
the Colorado Convention Center in Denver, Colorado.
AEZS-126 (Poster #3705)
- Entitled, "AEZS-126, a new orally bioavailable PI3K inhibitor with
antitumor effects", I. Seipelt, S. Baasner, M. Gerlach, M. Teifel, J.
Fensterle, L. Blumenstein, G. Mueller and E. Guenther, the poster
focuses on ADMET and safety profiling of the compound, as well as in
vivo pharmacokinetic experiments and mouse xenograft antitumor studies.
AEZS-126 (Poster #3706)
- Entitled, "In vitro profiling of the potent and selective PI3K
inhibitor, AEZS-126", I. Seipelt, M. Gerlach, L. Blumenstein, G.
Mueller, M.Teifel, E. Polymeropoulos and E. Guenther, the poster
outlines the key in vitro characteristics of this compound that led to
its selection for in vivo development.
Both posters will be presented on Tuesday, April 21, 2009, between 8 a.m.
and 12 p.m. (MT), during the Experimental and Molecular Therapeutics 23
session in Hall B-F, Poster Section 35.
AEZS-112 (Poster #5567)
- Entitled, "Phase I dose-escalation, safety, and pharmacokinetic study
of weekly oral AEZS-112, a small molecule anticancer agent in patients
with advanced cancer and lymphoma", D. W. Northfelt, P. Griffin, H.
Block, H. Sindermann, M. Teifel, D. Von Hoff, D. Mendelson, the poster
outlines Phase 1 results for this orally-active tubulin and
topoisomerase II inhibitor compound, in patients with advanced solid
tumors and lymphoma, which may potentially provide a new therapeutic
approach for the treatment of cancer.
The poster will be presented on Wednesday, April 22, 2009, between 8 a.m.
and 12 p.m. (MT) during the Experimental and Molecular Therapeutics 42 session
in Hall B-F, Poster Section 37.
Copies of the abstracts that served for these posters are currently
available and can be viewed on-line through the AACR 2009 Meeting website at:
About AEterna Zentaris Inc.
AEterna Zentaris Inc. is a global biopharmaceutical company focused on
endocrine therapy and oncology, with proven expertise in drug discovery,
development and commercialization. News releases and additional information
are available at www.aezsinc.com.
This press release contains forward-looking statements made pursuant to
the safe harbor provisions of the U.S. Securities Litigation Reform Act of
1995. Forward-looking statements involve known and unknown risks and
uncertainties, which could cause the Company's actual results to differ
materially from those in the forward-looking statements. Such risks and
uncertainties include, among others, the availability of funds and resources
to pursue R&D projects, the successful and timely completion of clinical
studies, the ability of the Company to take advantage of business
opportunities in the pharmaceutical industry, uncertainties related to the
regulatory process and general changes in economic conditions. Investors
should consult the Company's quarterly and annual filings with the Canadian
and U.S. securities commissions for additional information on risks and
uncertainties relating to the forward-looking statements. Investors are
cautioned not to rely on these forward-looking statements. The Company does
not undertake to update these forward-looking statements. We disclaim any
obligation to update any such factors or to publicly announce the result of
any revisions to any of the forward-looking statements contained herein to
reflect future results, events or developments except if we are requested by a
governmental authority or applicable law.
For further information:
For further information: Investor Relations: Ginette Vallières, Investor
Relations Coordinator, (418) 652-8525 ext. 265, firstname.lastname@example.org; Media
Relations: Paul Burroughs, Director of Communications, (418) 652-8525 ext.